seems like excellent results. Let’s see what announcement pops before open and how well the market interprets it
At data cut-off (Jan 2022), 75 pts with a minimum follow-up of 6 months were evaluated for efficacy. ORR (iRECIST) was 37.3% in the ITT and 41.8%% in the evaluable pts assessed by local read. DCR 73.3% was reported. Response rate for squamous and non-squamous pathology were 33.3 % and 40.3 %, respectively. Results according to RECIST 1.1 were comparable. Responses were observed in all PD-L1 subgroups (Table). 24/28 (86%) responses were already confirmed while median duration of response was not yet reached (5 events).seems like very good results. Let’s see how long it takes the market to ascribe a value to it:
enjoy the weekend all!
cheers,
YS
Ann: Immutep to announce new TACTI-002 data at ASCO 2022, page-47
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
-0.005(1.67%) |
Mkt cap ! $428.5M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 31.3¢ | 29.3¢ | $1.323M | 4.421M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 111754 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.0¢ | 61590 | 3 |
View Market Depth
| Last trade - 16.10pm 17/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |